NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation
Open Access
- 14 August 2007
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 97 (5) , 659-669
- https://doi.org/10.1038/sj.bjc.6603906
Abstract
Activation of NF-κB in inflammatory breast cancer (IBC) is associated with loss of estrogen receptor (ER) expression, indicating a potential crosstalk between NF-κB and ER. In this study, we examined the activation of NF-κB in IBC and non-IBC with respect to ER and EGFR and/or ErbB2 expression and MAPK hyperactivation. A qRT–PCR based ER signature was evaluated in tumours with and without transcriptionally active NF-κB, as well as correlated with the expression of eight NF-κB target genes. Using a combined ER/NF-κB signature, hierarchical clustering was executed. Hyperactivation of MAPK was investigated using a recently described MAPK signature ( Creighton et al, 2006), and was linked to tumour phenotype, ER and EGFR and/or ErbB2 overexpression. The expression of most ER-modulated genes was significantly elevated in breast tumours without transcriptionally active NF-κB. In addition, the expression of most ER-modulated genes was significantly anticorrelated with the expression of most NF-κB target genes, indicating an inverse correlation between ER and NF-κB activation. Clustering using the combined ER and NF-κB signature revealed one cluster mainly characterised by low NF-κB target gene expression and a second one with elevated NF-κB target gene expression. The first cluster was mainly characterised by non-IBC specimens and IHC ER+ breast tumours (13 out of 18 and 15 out of 18 respectively), whereas the second cluster was mainly characterised by IBC specimens and IHC ER− breast tumours (12 out of 19 and 15 out of 19 respectively) (Pearson χ2, PP<0.0001 respectively). Hyperactivation of MAPK was associated with both ER status and tumour phenotype by unsupervised hierarchical clustering using the MAPK signature and was significantly reflected by overexpression of EGFR and/or ErbB2. NF-κB activation is linked to loss of ER expression and activation in IBC and in breast cancer in general. The inverse correlation between NF-κB activation and ER activation is due to EGFR and/or ErbB2 overexpression, resulting in NF-κB activation and ER downregulation.Keywords
This publication has 37 references indexed in Scilit:
- Nuclear Factor-κB Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-κB DNA-BindingClinical Cancer Research, 2006
- Activation of Mitogen-Activated Protein Kinase in Estrogen Receptor α–Positive Breast Cancer Cells In vitro Induces an In vivo Molecular Phenotype of Estrogen Receptor α–Negative Human Breast TumorsCancer Research, 2006
- Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profilingBreast Cancer Research and Treatment, 2005
- Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray AnalysisBreast Cancer Research and Treatment, 2005
- Gene expression signature of estrogen receptor α status in breast cancerBMC Genomics, 2005
- Update on inflammatory breast cancerBreast Cancer Research, 2005
- Understanding breast cancer risk - where do we stand in 2005?Journal of Cellular and Molecular Medicine, 2005
- Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancersThe International Journal of Biochemistry & Cell Biology, 2004
- The nuclear factor kappa B (NF-κB): A potential therapeutic target for estrogen receptor negative breast cancersProceedings of the National Academy of Sciences, 2001
- Molecular portraits of human breast tumoursNature, 2000